For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP). The Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON) investigated the efficacy of thalidomide added to MP (MP-T) in a randomized phase III trial. The objective of this study was to investigate the efficacy, toxicity, and effects on quality of life of MP-T.
INTRODUCTION
For several decades, melphalan plus prednisone (MP) was the standard treatment for elderly patientswithmultiplemyeloma(MM).Severalchemotherapeutic combinations have been tried to improve the treatment outcome, but in a metaanalysis, it was shown that no benefit on overall survival (OS) was obtained. 1 It also became clear that the addition of interferon alfa to MP resulted in a small improvement in event-free survival (EFS); however, no improvement was seen in OS. 2 Singhal et al 3 described for the first time a beneficial effect of thalidomide in refractory MM patients. Several phase I and II studies confirmed the positive effect of thalidomide and showed that better response rates were obtained if thalidomide was combined with dexamethasone. [4] [5] [6] The Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) started a phase III study to compare the standard MP therapy with MP plus thalidomide (MP-T) in newly diagnosed elderly patients with MM. Before accrual was completed, publications of two trials showed a beneficial effect of the addition of thalidomide to MP treatment in elderly patients, although at the time of publication, these two studies were not conclusive with respect to OS, with a survival benefit in the Intergroupe Francophone du Myélome (IFM) study that was not confirmed in the Italian study. 7, 8 Based on recommendations of the data safety monitoring board, it was decided to stop the HOVON study at an accrual of 344 of the estimated 420 patients because the required number of events had been reached.
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PATIENTS AND METHODS
Study Design
The trial was designed as an open-label, multicenter, phase III randomized study in which standard MP was compared with MP-T in patients with previously untreated MM older than age 65 years. The primary objective was to measure the effect of the addition of thalidomide on EFS. Secondary end points were response, OS, and progression-free survival (PFS). The safety and toxicity of MP-T were also assessed including quality of life (QOL).
The central ethics committee and the local ethics committee of each participating hospital approved the study. The study was performed according to the Declaration of Helsinki, and all patients gave their written informed consent. The trial was registered under ISRCTN 90692740.
Patient Selection
Patients older than age 65 years with a newly diagnosed stage IB, II, or III MM, a WHO performance status of 0 to 3, and a measurable tumor parameter were eligible. Exclusion criteria were the presence of amyloid light-chain amyloidosis; polyneuropathy; severe cardiac, pulmonary, and hepatic dysfunction; renal failure with dependency on dialysis; uncontrolled infection of any kind or HIV positivity; and other malignancies. Pretreatment with chemotherapy or corticosteroids was not allowed.
Treatment Schedule
Melphalan 0.25 mg/kg and prednisone 1 mg/kg were administered daily for 5 days every 4 weeks. In MP-T, thalidomide 200 mg/d was administered continuously until 4 weeks after the last MP-T cycle. Eight cycles of MP or MP-T were planned. In case of an ongoing response, MP or MP-T cycles were continued until a plateau phase was reached. Patients who completed the planned MP-T cycles received maintenance therapy with thalidomide 50 mg/d until progression. Patients in the MP arm received no maintenance. After disease progression or no response, salvage therapy was given according the physician's choice.
Treatment with bisphosphonates was recommended using either pamidronate or clodronate. From 2007, a maximum treatment period of 2 years was recommended in patients without active disease.
At the start of the trial, no guidelines for thrombosis prophylaxis were given. From 2005, low molecular weight heparin (nadroparin 2,850 U anti-Xa or 5,700 U anti-Xa in case of weight Ͼ 90 kg) was recommended as standard prophylaxis during MP-T, whereas during maintenance, low-dose aspirin was advised. 9 It is unknown how many patients received thrombosis prophylaxis.
Study End Points
Response analysis was performed after three, six, and eight cycles; after the last MP/MP-T cycle; and yearly during maintenance or follow-up. Responses were scored according to the European Bone Marrow Transplantation Group criteria. 10 Complete response (CR) was defined as complete disappearance of M protein confirmed by immunofixation and bone marrow plasma cells less than 5%. Very good partial response (VGPR) was defined as a decrease of more than 90% of the M protein. Partial response (PR) was defined as a decrease of the M protein of more than 50% but less than 90%. Minimal response was defined as a decrease of the M protein of more than 25% but less than 50%. Progressive disease required an increase of more than 25% of serum M protein, with an absolute increase of more than 5 g/L or more than 25% of 24-hour urine M protein; development of new lesions; or an increase of more than 25% in pre-existing bone lesions or soft tissue plasmacytomas. A plateau phase was reached if stable M proteins were present for at least 3 months. Toxicity of the two regimens was assessed by laboratory evaluation, physical examination, vital signs, and adverse events assessments. Adverse events were scored using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 2.0.
EFS was defined as the time from registration to induction failure, death, progression, or relapse, whichever occurred first. OS was measured from time of registration. Patients still alive or lost to follow-up were censored at the date they were last known to be alive. PFS was measured from the time of achievement of PR or CR to the date of relapse, disease progression, or death from any cause.
QOL Analysis
The 
Statistical Analyses
The sample size estimation was based on EFS as the primary end point. A relative hazard rate of 0.7 for the MP-T arm corresponded with an increase in EFS from 60% to 70% at 1 year and from 15% to 27% at 5 years. For the detection of this difference with an ␣ ϭ .05 (two-sided) and a power of 80%, 252 events were required. This number of events might be expected after recruitment of 420 patients in 4.5 years and an additional follow-up time after inclusion of the last patient of 1 year.
Differences in response rates were tested using a 2 test for differences in proportions. A log-rank test was used to test the differences in EFS, OS, and PFS by random assignment arm. Multivariate Cox regression analysis was used to adjust the effect of random assignment on EFS, OS, and PFS for the influence of other prognostic factors. Random assignment was performed by the HOVON data center. All analyses were performed according to the intentto-treat principle.
RESULTS
Patient Accrual
The accrual of patients started in September 2002. In July 2007, the data safety monitoring board stopped the trial when 344 patients had been included based on two publications that indicated a superior effect of MP-T compared with MP alone. 7, 8 Eleven patients were excluded because they did not comply with the entry criteria (five had nonsecreting MM, one had no MM, one had stage IA MM, one had other malignancy, one provided no informed consent, and two were not evaluable).
Patients and Treatment
Three hundred thirty-three patients were analyzed (186 men and 147 women; median age, 72 years; range, 65 to 87 years). Thirty percent of patients were Ն 75 years old. The patients were well balanced for age, International Staging System stage, disease characteristics, and WHO performance status (Table 1) . One hundred sixty-eight patients received 1,011 cycles of MP, and 165 patients received 970 cycles of MP-T; in the both arms, the median and mean number of cycles was four cycles and six cycles, respectively. The median follow-up time at the date of analysis was 39 months (Fig 1) .
Response Rate
MP-T resulted in a significantly better response rate (CRϩVGPRϩPR) on protocol treatment than MP (66% v 45%, respectively; P Ͻ .001). CR was relatively low because immunofixation had not been mandatorily performed. After eight cycles, CRϩVGPR was 23% with MP-T versus 8% with MP (P Ͻ .001). No effect of age on the difference by arm was observed, with a response rate in patients Ն 75 years old of 66% in the MP-T arm and 44% in the MP arm (CRϩVGPR of 23% and 13%, respectively). The number of nonresponders or patients with progressive disease was 55% with MP and 34% with MP-T (P Ͻ .001). Figure 2 shows the time to response for overall response (Fig 2A) and VGPRϩCR (Fig 2B) . After three cycles of MP-T, 58% of patients had achieved at least PR compared with 32% of patients on MP (P Ͻ .001).
Prolonged Treatment, Maintenance, and Second-Line Therapy
Nineteen patients on MP and 18 patients on MP-T received more than eight cycles until reaching a plateau level of M protein. This ongoing treatment led to a small increase from PR to VGPR of 2% in both arms.
Sixty-five (88%) of 74 eligible MP-T-treated patients received thalidomide as maintenance, with a median duration of 255 days (5% to 95% range, 43 to 1,094 days). Thalidomide-induced polyneuropathy (TiPN) was the main reason not to give or to stop maintenance therapy. During maintenance, an increase of CRϩVGPR from 23% to 28% was observed.
Induction failure or disease progression during protocol treatment was observed in 52 patients in the MP arm and 18 patients in the MPT arm. The exact salvage treatment given because of progressive disease is not known, but a substantial number of patients (96 of 120 patients) from the MP arm received thalidomide as second-line therapy.
Survival
The median EFS was 9 months with MP and 13 months with MP-T (P Ͻ .001; Fig 3) . The 2-year EFS was significantly better with MP-T than MP (29% v 10%, respectively; P Ͻ .01).
Median PFS from CR/PR was 15 months for MP-T compared with 11 months for MP (P Ͻ .002; Fig 3) . The difference in PFS at 2 years was 34% with MP-T and 14% with MP. PFS from time of registration was also significantly better in patients treated with MP-T versus MP (33% v 21%, respectively; P Ͻ .05).
OS of patients treated with MP-T was significantly better than the OS of those treated with MP (40 v 31 months, respectively; P ϭ .05). The 2-and 4-year OS rates were 67% and 43%, respectively, for MP-T compared with 61% and 30%, respectively, for MP. The multivariate Cox regression analysis of the most significant variables for response, EFS, PFS, and OS is shown in Table 2 .
Even in the elderly (Ն 75 years old), we observed an improvement in EFS (P Ͻ .003), although the median EFS was shorter (6 months for MP and 10 months for MP-T). In addition, the PFS was improved (P ϭ .03) but not the OS (Fig 3) .
In the multivariate analysis, WHO grade 2 or 3 appeared to be the strongest prognostic factor for OS, whereas MP versus MP-T was not significant. Therefore, we determined whether a different impact on OS with MP-T was present according to WHO grade. The multivariate analysis was extended with terms for interaction between arm of random assignment (MP-T v MP) and WHO grade. For WHO grade 1, the hazard ratio was 0.756, and for WHO grade 2 or 3, the hazard ratio was 1.536 (P for the two added terms of interaction ϭ .069). Hence, the data indicate that an unfavorable clinical condition at baseline may be associated with the absence of a favorable effect of thalidomide on OS.
Toxicity
Treatment discontinuation as a result of toxicity in the MP arm was rather low (Fig 1) . Neutropenia-related infection was probably the main reason, but only four of the 17 early deaths were related to an infection. MP-T was associated with a higher rate of toxicity. Treatment-related adverse effects of WHO grade 2 or higher occurred in 60% of MP-treated patients compared with 87% of MP-T-treated patients ( Table 3 ). The higher rate of toxicity with MP-T was primarily due to TiPN, with NCI CTC grade 3 or 4 neuropathy being observed in 23% of patients. During maintenance, grade Ն 2 TiPN was observed in 54% of patients. Venous thrombotic events occurred in 10% of MP-T-treated patients compared with only 1% of MP-treated patients. Treatment-related adverse events were the reason for going off study for 11 patients in the MP arm and 62 patients in the MP-T arm.
Given the relatively high dose of melphalan in this trial, dose reductions were required in 70% of patients, with no difference between MP and MP-T arms. One third of the patients treated with MP-T needed dose reductions of thalidomide (27%, 35%, and 34% at 3, 6, and 8 months of treatment, respectively). Table 4 lists the number of patients still in the protocol at the different time points and the number of patients who needed dose reductions for the different drugs.
Cytogenetics
Cytogenetic analysis using conventional karyotype banding techniques was successfully performed in 94 and 88 patients in the MP and MP-T arms, respectively. In patients with a complete or partial deletion of chromosome 13 (n ϭ 33), no effect on response, EFS, PFS, or OS was observed in either treatment arm.
QOL
Two hundred eighty-five of 333 eligible patients participated in the QOL study. For most QOL subscales, a trend for improvement was observed during the treatment. There were no subscales indicating an unfavorable or favorable influence of thalidomide. The details of the QOL study will be presented separately. 
DISCUSSION
Recently, three trials showed an improved response rate with MP-T. 7, 8, 12 Another trial from the Nordic group reported relatively high rates of early toxicity with MP-T and moderate gains in response. 13 This HOVON trial confirms the superior effect of MP-T over MP on response rate. In addition, the time to response and quality of the response are significantly better because more patients achieve a VGPR or better with MP-T. MP-T also results in a longer EFS and PFS. In addition, a significant effect on OS has been observed at a follow-up time of 39 months. The response rate of this trial is comparable with the other MP-T versus MP trials, with rates ranging from 42% in the Nordic trial to 76% in the Italian and French trials.
As in the Italian and both French trials, we observed a superior EFS and PFS with MP-T. The results on OS differ among the studies.
The OS of 40 months with MP-T is comparable with the results of the French and Italian trials. However, a significant difference between MP-T and MP has only been observed in both IFM trials and this HOVON trial. 8, 12 In the Italian study, the better response rate and EFS with MP-T did not lead to an OS benefit, even in an updated analysis. 14 Comparing the response and survival data of the different studies is difficult because of the different dosing schedules of MP and MP-T. The melphalan dose in the HOVON study was higher than in any other trial. However, the differences in EFS and OS cannot easily be explained by the dosing of either melphalan or thalidomide. These drugs were given at a lower dose in one IFM study and in the Nordic study, with a survival advantage seen in the IFM trial only. 7, 13 In the IFM study, in patients older than age 75 years, significantly lower doses of MP-T were given; however, a beneficial effect of thalidomide on OS was still observed. 13 The HOVON study also shows an improvement in response rate and EFS in patients Ն 75 years old. However, the multivariate analysis with terms for interaction between arm and WHO status at entry indicated the absence of a favorable effect of thalidomide among patients with an unfavorable clinical condition at baseline.
In the Italian study, the thalidomide dose was relatively low, although maintenance with thalidomide was allowed. 7 A trial in younger patients treated with high-dose therapy showed improvement in EFS and a late effect on OS in only certain cytogenetic subgroups with the use of thalidomide. 15 More recently, no effect of thalidomide on OS was observed in the HOVON 50 trial.
16
MP-T may be superior to thalidomide plus dexamethasone because Ludwig et al 17 found this combination to be inferior to MP regarding OS and toxicity. Whether MP-T is superior to the combination of cyclophosphamide, thalidomide, and dexamethasone, which did show promising activity in patients with relapsed disease, remains to be studied. 18 In our study, the dose of melphalan was higher than in other studies. This might explain the high incidence of myelotoxicity in both arms. Thalidomide added significant neurotoxicity as the most significant adverse effect. GI adverse effects that may be related to intestinal Abbreviations: IgA, immunoglobulin A; IgG, immunoglobulin G; MP, melphalan and prednisone; MP-T, melphalan, prednisone, and thalidomide; EFS, event-free survival; PFS, progression-free survival; CR, complete response; PR, partial response; OS, overall survival. 8  4  24  23  GI  16  7  24  5  Pain  7  8  11  4  Lung  10  3  14  3  Thrombosis  1  0  7  3  Infections  15  18  7  28 Abbreviations: NCI CTC, National Cancer Institute Common Toxicity Criteria; MP, melphalan and prednisone; MP-T, melphalan, prednisone, and thalidomide. neuropathy were the second most important complication. Although thalidomide induced significant toxicity in MP-T-treated patients, it did not result in a reduction of the number of MP-T cycles that could be given when compared with the MP group. This toxicity also did not lead to a significant difference in dose reduction or affect QOL. At the start of the study, no guidelines were given for thrombosis prophylaxis. Later, low-dose heparin was recommended. We do not have data on how many patients received prophylactic therapy, but a low incidence of NCI CTC grade 3 or 4 thrombosis was observed.
An open question is whether there are subpopulations of patients who benefit from thalidomide and those who experience only the adverse effects. From the different cytogenetic subgroups that we analyzed, no specific effect of 13q deletions was observed, although only 33 patients had this abnormality.
Maintenance therapy may have a favorable effect on outcome because we observed a further improvement of the quality of the response during maintenance. Two other studies have shown that maintenance or consolidation treatment when given to younger patients after intensive chemotherapy has a positive effect on OS. 19, 20 In MP-T trials, the role of maintenance therapy remains unclear because, of the three trials with OS benefit, only the HOVON trial included maintenance treatment. Benefit of this maintenance treatment was seen, but a substantial number of patients experienced TiPN and had to stop maintenance treatment. As such, the role of maintenance treatment using other novel agents is still under investigation. We conclude that MP-T is an effective regimen for older patients with newly diagnosed MM with a clear benefit on survival.
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